Testing neladalkib for untreated ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic non-small cell lung cancer (NSCLC) that has spread and cannot be treated with surgery or radiation alone.
- Your tumor has a specific ALK gene change (rearrangement) confirmed by a tissue or blood test.
- You have not had any prior treatment for advanced lung cancer, except for certain chemotherapy before surgery or radiation if it was more than 12 months ago.
- You have at least one tumor that can be measured on scans (like a CT scan).
- You are willing to provide a sample of your tumor tissue before starting the study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program provides early access to the drug neladalkib for people with advanced ALK-positive non-small cell lung cancer or other ALK-positive solid tumors who have run out of standard treatment options and cannot join a clinical trial.
This trial compares a new targeted pill (SY-3505) to the current standard drug (crizotinib) as a first treatment for people with advanced ALK-positive non-small cell lung cancer (NSCLC). It aims to find out which drug works better and has fewer side effects.
This trial tests giving alectinib first, then adding targeted radiation to remaining spots of cancer in people with ALK-rearranged advanced non-small cell lung cancer. It aims to control the cancer after an initial response and help keep disease from progressing.
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
This early-phase trial studies how alectinib (an ALK-blocking medicine) moves through the body and how it’s tolerated in people with advanced non-small cell lung cancer (NSCLC) that has an ALK rearrangement. You may be considered if you have ALK-positive, recurrent or advanced disease and have already had specific prior treatments.
This study looks at how people with advanced ALK-positive non-small cell lung cancer (NSCLC) respond to the targeted drug lorlatinib. It aims to understand whether local treatments (like radiation or surgery) are needed during therapy. If you have this type of lung cancer and haven't had treatment yet, this study might be an option.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.